demonstrating a favorable safety and tolerability profile over the 12-week treatment period and 4-week follow-up. While not powered for statistical efficacy, the study showed promising trends favoring ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

thereby suggesting an improved GI tolerability of meloxicam compared with other less selective NSAIDs.

Objective: The aim of the present study was to monitor the efficacy and tolerability of glimepiride in daily practice. Design: An 8-week non-interventional cohort study investigating glimepiride ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...

While Recursion’s superoxide scavenger scored a hit on the primary endpoint of safety and tolerability, the efficacy data ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Other clinical research includes interim results from an investigator-initiated phase 1 trial evaluating the safety and ...

atai expects to initiate an exploratory, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

"We are moving rapidly to advance CT1812 in Alzheimer's disease and plan to request an end-of-Phase 2 meeting with the FDA where we will review CT1812's safety and tolerability profile as well as the ...